Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-925 in seasonal allergic conjunctivitis
NCT07220408Phase 2Recruiting
- Sponsor
- Telios Pharma
- Start
- Oct 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TL-925 in seasonal allergic conjunctivitis (SAC), sponsored by Telios Pharma. Started Oct 2025; status: recruiting.
02
Drugs
TL-925
03
Conditions
seasonal allergic conjunctivitis (SAC)
Beyond the preview
Go deeper on NCT07220408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220408.